{"protocolSection":{"identificationModule":{"nctId":"NCT06481826","orgStudyIdInfo":{"id":"Glofitamab-1"},"organization":{"fullName":"Peking Union Medical College Hospital","class":"OTHER"},"briefTitle":"Glofitamab in Chinese Patients With R/R DLBCL","officialTitle":"A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-01-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-12","studyFirstSubmitQcDate":"2024-06-28","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-28","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Peking Union Medical College Hospital","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy."},"conditionsModule":{"conditions":["DLBCL - Diffuse Large B Cell Lymphoma"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"3 Years","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":20,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"treatment group","description":"Glofitamab","interventionNames":["Drug: Glofitamab"]}],"interventions":[{"type":"DRUG","name":"Glofitamab","description":"Glofitamab given in standard dosage","armGroupLabels":["treatment group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"PFS","description":"Progression-free survival","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"OS","description":"overall survival","timeFrame":"2 year"},{"measure":"CR rate","description":"complete response","timeFrame":"6 weeks, 18 weeks, 36 weeks"},{"measure":"ORR","description":"overall response rate","timeFrame":"6 weeks, 18 weeks, 36 weeks"},{"measure":"DOR","description":"duration of response","timeFrame":"2 year"},{"measure":"AE","description":"Rate and type of adverse events (AEs) and serious adverse events (SAEs)","timeFrame":"2 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Histologically-confirmed DLBCL\n2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy\n3. Participants must have measurable disease\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Patient with known active infection, or reactivation of a latent infection\n3. Patient with active autoimmune disease or immune deficiency\n4. severe organ failure：LVEF\\<40%；DLCO\\<40%；eGFR\\<30ml/min；Bilirubin≥3ULN\n5. Patients who are dependent on the sponsor, the investigator or the trial site","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Jing Ruan","role":"CONTACT","phone":"+8615201435860","email":"15201435860@163.com"}],"locations":[{"facility":"Peking Union Medical College Hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100730","country":"China","contacts":[{"name":"Wei Zhang","role":"CONTACT","email":"zhangwei3840@126.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"references":[{"pmid":"36507690","type":"BACKGROUND","citation":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wrobel T, Offner F, Trneny M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11."},{"pmid":"37211991","type":"BACKGROUND","citation":"Birtas Atesoglu E, Gulbas Z, Uzay A, Ozcan M, Ozkalemkas F, Dal MS, Kalyon H, Akay OM, Deveci B, Bekoz H, Sevindik OG, Toptas T, Yilmaz F, Koyun D, Alkis N, Alacacioglu I, Sonmez M, Yavasoglu I, Tombak A, Mehtap O, Kurnaz F, Yuce OK, Karakus V, Turgut M, Kurekci DD, Ayer M, Keklik M, Buyuktas D, Ozbalak M, Ferhanoglu B. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. Hematol Oncol. 2023 Oct;41(4):663-673. doi: 10.1002/hon.3174. Epub 2023 May 22."},{"pmid":"37855035","type":"BACKGROUND","citation":"Song YQ, Zhang HL, Huang HQ, Zhang QY, Jing HM, Wang C, Wu C, Li DH, Dai Y, Humphrey K, Zhu J. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2024 Apr 1;109(4):1269-1273. doi: 10.3324/haematol.2023.283802. No abstract available."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"the study protocol, statistical analysis plan, informed consent form, clinical study report would be available upon email request in 3 years after the closure of the study","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"3 years after the closure of the study","accessCriteria":"upon email request"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008223","term":"Lymphoma"},{"id":"D000016393","term":"Lymphoma, B-Cell"},{"id":"D000016403","term":"Lymphoma, Large B-Cell, Diffuse"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"}],"browseLeaves":[{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M18828","name":"Lymphoma, B-Cell","asFound":"B-cell Lymphoma","relevance":"HIGH"},{"id":"M18831","name":"Lymphoma, Large B-Cell, Diffuse","asFound":"Diffuse Large B-Cell Lymphoma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","relevance":"LOW"},{"id":"T640","name":"B-cell Lymphoma","asFound":"B-cell Lymphoma","relevance":"HIGH"},{"id":"T1866","name":"Diffuse Large B-Cell Lymphoma","asFound":"Diffuse Large B-Cell Lymphoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}